Key Takeaways
- ACXP shares exploded more than 218% during the week following news of a new clinical trial for ibezapolstat, its flagship antibiotic.
- Phase 2 data revealed ibezapolstat achieved a 96% cure rate in treating C. difficile infection (CDI), with no recurrence among successfully treated patients.
- A 20-patient open-label pilot study targeting recurrent CDI is underway, paving the way for a comprehensive Phase 3 registration trial.
- Both U.S. and European regulatory agencies have approved Acurx’s pathway to commence global Phase 3 clinical studies.
- Annual 2025 net loss decreased to $8.0 million from $14.1 million previously, while cash reserves rose to $7.6 million.
Acurx Pharmaceuticals (ACXP) delivered one of the biotech sector’s most dramatic performances this year. Shares skyrocketed more than 218% over a five-day period following the company’s disclosure of a new clinical trial initiative for ibezapolstat, its primary antibiotic candidate designed to combat C. difficile infection.
Acurx Pharmaceuticals, Inc., ACXP
The majority of the rally materialized after Monday’s announcement outlined the framework for Phase 3 development. Come Friday morning, shares tacked on an additional 3.59% during pre-market hours immediately after the company released its Q4 financial results.
C. difficile infection, commonly abbreviated as CDI, represents a bacterial gastrointestinal illness notorious for its recurring nature. Patients experiencing three or more episodes within a 12-month span face severely constrained treatment alternatives, and recurrence remains a persistent challenge.
The Phase 2 results for ibezapolstat provided substantial material for investor optimism. The compound achieved a 96% clinical cure rate among 26 participants diagnosed with acute CDI. Even more remarkable — every successfully treated patient remained infection-free throughout the entire monitoring period.
This dual capability of both treating and preventing recurrence represents what Acurx considers ibezapolstat’s key differentiator. Existing therapies typically address the active infection but fail to prevent subsequent episodes.
The organization is initiating a 20-patient open-label pilot study concentrating exclusively on individuals suffering from multiply-recurrent CDI — specifically those who have endured a minimum of three episodes within the preceding year. Data gathered from this pilot will inform the structure of the comprehensive Phase 3 registration trial.
Regulatory Approval Secured
Among this week’s most significant developments was verification that regulatory authorities in both the United States and Europe have provided Acurx with an unambiguous framework to initiate international Phase 3 clinical studies. This type of bilateral regulatory endorsement eliminates substantial uncertainty for a small-capitalization biotechnology firm.
It further demonstrates that the company’s strategy extends beyond domestic trials — the program incorporates international expansion from inception.
In February 2026, Acurx secured an additional patent covering its Pol IIIC inhibitors, extending intellectual property protection until December 2039. That represents considerable market exclusivity should the drug ultimately achieve commercialization.
Fourth Quarter Results: Deficit Reduction
Regarding financial performance, Acurx disclosed a Q4 2025 loss of $5.32 per share, exceeding the $3.29 loss recorded in Q4 2024. However, the annual figures present a more encouraging narrative.
Throughout 2025, the net loss totaled $8.0 million versus $14.1 million during 2024 — representing substantial improvement. Research and development expenditures declined to $0.3 million from $0.8 million, while general and administrative costs fell to $1.3 million from $2.0 million.
Cash position strengthened as well. Acurx concluded December 31, 2025 holding $7.6 million in cash, increased from $3.7 million twelve months prior. This establishes a more robust financial foundation entering the trial phase.
Currently, two Wall Street analysts maintain a Moderate Buy rating on ACXP, establishing a consensus 12-month price target of $17.50.
At the time of Friday morning’s earnings announcement, shares were exchanging hands with a 3.59% pre-market increase following validation of the new rCDI trial commencement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
